Oncolytics Biotech Inc reports results for the quarter ended September 30 - Earnings Summary

• Oncolytics Biotech Inc ONC.TO reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -14 cents. The mean expectation of six analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -11 cents to -9 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Oncolytics Biotech Inc's reported EPS for the quarter was a loss of 12 cents​.

• The company reported a quarterly loss of $9.54 million.

• Oncolytics Biotech Inc shares had risen by 24.0% this quarter and lost 20.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Oncolytics Biotech Inc is $4.73

This summary was machine generated from LSEG data November 12 at 01:39 p.m. UTC. ​All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)